Eli Lilly has called on financial regulators to ... The issue was also alluded to by Lilly’s chief financial officer, Anat Ashkenazi, on the company’s fourth-quarter results call yesterday ...

One of the highlights of Eli Lilly's third-quarter results ... said Lilly's chief financial officer Anat Ashkenazi on the call. Now, Lilly's focus is on international expansion – with approvals ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced today that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to explore a new career... ByInvesting.com ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.